Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib + trastuzumab/carboplatin/docetaxel neoadjuvant study in HER2-positive breast cancer
ChiCTR1800020226Phase 3Not yet recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Feb 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of pyrotinib in breast cancer, sponsored by Sir Run-Run Shaw Hospital. Primary endpoints: Total pathologic complete response and Biomarker. Planned start Feb 2019; status: not yet recruiting.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR1800020226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800020226.